1. Physical Dose Is Only Half the Story

Delivering 60 Gray in a single instantaneous irradiation produces catastrophically different biological consequences than delivering 60 Gray divided into 30 daily 2 Gy fractions over six weeks. Although physical absorbed dose (energy per unit mass, 1 Gy = 1 J/kg) is identical in both scenarios, mammalian cells continuously repair sublethal DNA damage, redistribute across radiosensitive cell-cycle phases, reoxygenate hypoxic clonogens, and repopulate between treatment fractions.

The mathematical backbone unifying physical dosimetry and clinical radiation oncology is the Linear-Quadratic (LQ) model of clonogenic cell survival, parameterized experimentally by α, β, the α/β ratio, Biologically Effective Dose (BED), and Equivalent Dose in 2 Gy fractions (EQD2).

2. Mechanistic Origin of S = exp(-αD - βD²)

Ionizing radiation kills proliferating cells primarily through clustered DNA double-strand breaks (DSBs) that lead to lethal chromosomal aberrations (such as dicentrics and acentric fragments) and mitotic catastrophe. Within the Chadwick-Leenhouts and Lea-Catcheside framework, lethal DSB lesions originate through two stochastic pathways:

  • Linear Single-Track Component (αD): A single ionized particle track produces closely spaced breaks across both complementary DNA strands (or two adjacent sublethal lesions simultaneously). Because the probability of one track causing both lesions is directly proportional to fluence (hence physical dose D), single-track lethality contributes -αD to ln(S).
  • Quadratic Two-Track Component (βD²): Two separate, temporally independent particle tracks each induce a sublethal single-strand break or proximal lesion within repair distance. Before homologous recombination or non-homologous end joining (NHEJ) can restore integrity, the two sublethal breaks misrepair into a lethal aberration. Because independent two-track encounters scale with the square of dose, they contribute -βD².

If n equal fractions of dose d are separated by enough time (typically ≥ 6–24 hours) for complete sublethal damage repair, surviving fractions multiply independently across fractions: S_total = [exp(-αd - βd²)]ⁿ = exp[-n(αd + βd²)]. Observe that at dose d = α/β, we have αd = βd²: both mechanisms kill equal fractions of clonogens.

3. Deriving BED and EQD2 From Cell Survival

Withers introduced the concept of Biologically Effective Dose (originally extrapolated total dose, ETD) by dividing the logarithmic survival exponent by -α, yielding a quantity with units of dose (Gy) that linearly measures log cell kill for a given tissue:

E = -ln(S)/α = n·d·[ 1 + d / (α/β) ] = BED

Because clinical intuition and organ-at-risk toxicity tables (such as QUANTEC) are historically anchored to conventional 2 Gy daily fractionation, radiation oncologists convert BED into EQD2 by solving for the total physical dose D_2Gy delivered at d = 2 Gy that yields the same BED:

EQD2 = BED / (1 + 2 / (α/β)) = D · (d + α/β) / (2 + α/β)

Put these equations to work immediately with our Interactive BED & EQD2 Calculator and Clonogenic Cell Survival Calculator.

4. Interpreting Early vs. Late α/β Ratios in Clinical Oncology

Early-responding tissues (intestinal crypts, oral mucosa, bone marrow, epidermis, and most rapidly proliferating carcinomas such as head-and-neck squamous cell carcinoma, lung, and cervical cancers) display steep initial slopes on survival curves and modest shoulders, corresponding to high α/β ≈ 10 Gy (range 8–12 Gy). Late-responding normal organs (spinal cord, optic chiasm, brain parenchyma, lung fibrosis, kidney, heart, and rectum) repair sublethal damage efficiently at low doses per fraction and show pronounced survival curve shoulders, corresponding to low α/β ≈ 2–3 Gy.

This biological divergence creates the therapeutic window of conventional fractionation: lowering dose per fraction to 1.8–2.0 Gy shrinks the quadratic βd² damage sharply in late-responding organs while preserving linear αD lethality against fast-dividing tumors. Conversely, malignancies with unusually low intrinsic proliferation and low α/β ratios—most notably prostate adenocarcinoma (α/β ≈ 1.5 Gy) and, to a lesser degree, breast cancer (~3.5–4 Gy) and melanoma—actually show equal or greater biological sensitivity to larger doses per fraction, providing the radiobiological foundation for clinical hypofractionation and prostate SBRT.

5. The 5 Rs of Radiobiology

Beyond static single-cell survival curves, clinical fractionated radiotherapy engages five dynamic biological processes across hours to weeks:

  1. Repair of Sublethal Damage (SLDR): Between fractions (usually 6+ hours), intracellular DNA repair pathways fix single-strand lesions and restore the shoulder of the survival curve. Normal late-responding tissues typically repair more completely than genomically unstable tumors.
  2. Reassortment (Redistribution) Across the Cell Cycle: Mammalian cells exhibit markedly higher radiosensitivity in late G₂ and mitosis (M) and relative radioresistance in late S phase. Following a single dose that preferentially eliminates G₂/M cells, surviving S-phase cells progress through the cell cycle toward radiosensitive phases before the next daily fraction.
  3. Repopulation: Surviving stem cells in both acutely responding mucosa and solid tumors proliferate during protracted courses. In head-and-neck squamous cell carcinoma, accelerated tumor repopulation kicks in around weeks 3–4 of therapy (requiring approximately 0.6 Gy/day extra dose to overcome missed treatment days)—explaining why unplanned treatment breaks reduce locoregional control.
  4. Reoxygenation: Molecular oxygen acts as a potent electron-affinic radiosensitizer by fixing radiation-induced DNA free radicals into permanent strand breaks ("oxygen fixation hypothesis"). Hypoxic tumor cores are roughly 2.5–3.0× more radioresistant (Oxygen Enhancement Ratio, OER ≈ 2.5–3.0 for low-LET photons) than well-oxygenated cells. As fractionated doses kill and shrink well-vascularized outer tumor layers, diffusion distances shorten and blood vessels reopen, reoxygenating previously hypoxic clonogens.
  5. Radiosensitivity (Intrinsic): Distinct tumor histologies span wide intrinsic SF₂ ranges—from exquisitely radiosensitive seminoma and lymphoma to radioresistant glioblastoma, sarcoma, and melanoma—shaping clinical prescription doses from 20–36 Gy up to 70+ Gy.

Visualizing how α, β, fraction size, and number of fractions bend clonogenic survival curves is effortless inside our Interactive LQ Survival Canvas Simulator.

Next Steps in Radiation Oncology Physics